When teams lack accurate device visibility, they cannot segment effectively, prioritise remediation, or prove that risky assets are under control. In healthcare, that failure is amplified by proprietary protocols, long-lived devices, and clinical uptime constraints. The result is trust by assumption rather than by evidence, which creates avoidable exposure for IoMT and OT environments.
Why This Matters for Security Teams
When connected devices are not inventoried accurately, healthcare security teams lose the ability to distinguish monitored assets from unmanaged ones. That weakens segmentation, patch prioritisation, vulnerability triage, and incident response. In hospitals, the impact is more severe because medical devices often have long replacement cycles, proprietary management interfaces, and operational dependencies that make reactive controls risky. Guidance from NIST SP 800-207 Zero Trust Architecture reinforces a simple point: trust should be continuously verified, not inferred from network location or device appearance.
The practical problem is not just missing records. Unknown devices can create blind spots in asset criticality, owner accountability, and compensating controls. If a pump, imaging platform, workstation, gateway, or embedded sensor is not identified, the organisation cannot reliably decide whether it belongs in a clinical VLAN, whether it needs compensating segmentation, or whether it should be isolated pending review. That gap also makes audit evidence weaker because teams cannot demonstrate that high-risk assets are governed by a repeatable control process. In practice, many security teams encounter the real risk only after a discovery scan, alert, or vendor call exposes devices that were never formally brought into scope.
How It Works in Practice
Device visibility in healthcare should combine passive discovery, active verification, clinical validation, and ongoing governance. No single method is sufficient on its own. Passive network monitoring can identify MAC addresses, protocols, and communication patterns without interrupting care. Active techniques can confirm firmware, open services, and ownership details, but they must be carefully timed to avoid disrupting sensitive equipment. The best practice is to merge technical discovery with procurement, biomedical engineering, clinical engineering, and CMDB or asset register records so that each device is tied to a business owner and risk classification.
Operationally, teams usually need to answer five questions at once:
- What device is this, and what function does it perform?
- Who owns it, and who can approve changes?
- What network segment should it occupy?
- What protocols or services are essential for care delivery?
- What compensating controls apply if patching is delayed?
This is where Zero Trust and asset governance intersect. EU Cyber Resilience Act expectations around secure-by-design product accountability are not a substitute for local inventory, but they do reflect the direction of travel: organisations are expected to know what they deploy and how it is protected. In parallel, current guidance suggests that segmentation policy should be based on verified identity and function, not on assumptions about device type from network hints alone. That matters for IoMT, because many devices speak legacy protocols, cannot support agents, and may need network-based monitoring rather than host-based controls.
In mature environments, the inventory process also feeds change control and incident response. When a device appears unexpectedly, teams should compare it against approved procurement records, update risk status, and decide whether to quarantine, monitor, or exempt it with explicit time bounds. These controls tend to break down when medical devices are shared across departments without consistent ownership because nobody can reliably confirm who is accountable for exposure or remediation.
Common Variations and Edge Cases
Tighter device control often increases operational overhead, requiring organisations to balance clinical uptime against security assurance. That tradeoff is especially visible in emergency care, radiology, operating theatres, and ageing estates, where devices may be essential but difficult to patch or interrogate.
There is no universal standard for this yet, but current guidance suggests that exception handling should be explicit, temporary, and risk accepted by the right authority. A device that cannot be actively scanned may still be managed through passive telemetry, vendor attestations, maintenance windows, and compensating segmentation. The key is to avoid treating “cannot inspect” as “safe to trust.”
Healthcare teams also need to account for mixed environments. Some devices are conventional endpoints, some are embedded systems, and some behave more like OT assets than IT assets. That means ownership may sit with biomedical engineering, facilities, clinical operations, or an external service provider. When identity and access controls extend into these environments, the same principle applies: know the asset, know the operator, and know the privilege boundary. Without that clarity, even strong controls become brittle because the enforcement point is disconnected from actual clinical use.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
MITRE ATT&CK address the attack and risk surface, while NIST CSF 2.0 and NIST Zero Trust (SP 800-207) set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST CSF 2.0 | ID.AM-1 | Asset inventory is foundational when unknown devices weaken visibility and control. |
| MITRE ATT&CK | T1133 | Remote services on unmanaged devices can expand attacker access paths. |
| NIST Zero Trust (SP 800-207) | Zero Trust requires continuous verification of device trust, not assumptions from network location. |
Treat each connected device as untrusted until its identity, posture, and policy status are verified.
Related resources from NHI Mgmt Group
- How should security teams handle legacy network devices in NHI governance?
- How do security teams know if a connected app is overprivileged?
- How do security teams know whether an OAuth-connected app is operating outside its intended boundary?
- What breaks when healthcare teams rely on provisioning-time access for AI systems touching ePHI?
